IN THE CLAIMS:

1. (Amended) A compound having a structure that corresponds to the formula:



wherein

R_1, R_2, R_3 and R_4 are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid or where R_1R_2 or R_3R_4, taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group wherein the substituent is selected from halo, trifluoromethyl, lower alkyl and lower alkoxy;

R is a straight chained, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms;

Y is hydrogen, bromo, chloro or lower alkyl;

and X is selected from the group consisting of [carboxy,] hydroxy,[acetoxy,] alkanoyloxy having 1-6 carbon atoms, lower alkoxy, lower alkyl carbonyl, oximino, cyano, amino, [C(O)-R_5] and -C(O)C(O)-R_5 wherein R_5 is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR_6R_7 wherein R_6 and R_7 are the same or different and are selected from the group consisting of [hydrogen and lower alkyl, or R_6 or R_7 are selected from the group consisting

of] [hydrogen,] lower alkyl, lower alkoxy, hydroxy, [acyloxy,] lower alkanoyloxy having 1-6 carbon atoms, benzyloxy, 2-hydroxy lower alkyl, [lower alkyl carboxy,] carboxy lower alkyl, phenyl, substituted phenyl, wherein the substituent is selected from halo, trifluoromethyl, lower alkyl and lower alkoxy, pyridyl, thiazolyl, dihydrothiazolyl, 5-tetrazolyl, $-OCO(CH_2)_nCOR_9$ wherein R_9 is -OH, ONa, dialkylamino such as diethylamino and morpholino, and n is 2 or 3; $-OCOR_{10}$ wherein R_{10} is $-CH_2NR_{11}R_{12}$ wherein R_{11} and R_{12} are lower alkyl, [such as methyl,] [cycloalkyl such as] cyclohexyl, or together are [a heterocyclic ring such as] N-methylpiperazino, $-OCOR_{10}$ wherein R_{10} is $-CH_2Cl$, $-CH_2O$-loweralkyl or t-butyl, -CH-loweralkyl-CO_2-lower alkyl, $-CH_2CH_2NC_2H_5$, [acyl such as] acetyl, propionyl or butyryl; $-NR_8OH$ wherein R_8 is hydrogen, -CO-loweralkyl, -CO-t-butyl, $-COC_7H_{15}$, -CO-phenyl, $-SO_2$-lower alkyl, $-COCO_2$-lower alkyl, and -COCONHOH; $-NHR_{13}$ wherein R_{13} is hydrogen, -CO-lower alkyl, -CO-t-butyl, COC_7H_{15}, -CO-phenyl, $-SO_2$-lower alkyl, $-COCO_2$-lower alkyl, -COCONHOH, $-COCO_2H$, COCON(lower alkyl)OH, and PO(O-lower alkyl)$_2$; $-C(R_{14})$=NNH-2-thiazolino, $-CH(OH)R_{14}$ and $-C(O)R_{14}$ wherein R_{14} is hydrogen, [lower alkyl,] phenyl and t-butyl; $-C(=NOH)NH_2$ and -C(=NH)N(OH)-lower alkyl, [ω-alkanoate] and $O-NR_8R_9$ wherein R_8 and R_9 are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl wherein the substituent is selected from halo, trifluoro methyl, lower alkyl and lower alkoxy;

with the provisos that:

(a) when Y is bromo or chloro, X is -COOH, $-CH_2OH$ or $-C(O)-R_5$ wherein R_5 is NR_6R_7 and R_6 is OH and R_7 is lower alkyl;

(b) at least one of R_1 and R_2 is other than hydrogen where [(i) R-X is $(CH_2)_2CO_2H$ or $(CH_2)_2C(O)NHOH$, and (ii)] R_3 and R_4 are 4-methoxy, 3-methoxy-4-hydroxy, 2-hydroxy and hydrogen and

(c) at least one of R_1 and R_2, or of R_3 and R_4 is other than hydrogen where R-X together contains three saturated carbon atoms linked together by carbon-carbon bonds; and pharmaceutically acceptable salts thereof.

4. (Amended) The compound according to claim 3 wherein X is selected from the group consisting of hydroxy, [carboxy,] [a carboxylate salt of a pharmaceutically acceptable cation,] $C(O)-NR_6R_7$ wherein R_6 and R_7 are selected from the group consisting of [hydrogen,] hydroxyl, methyl, t-butyl, 2-hydroxyethyl and carboxymethyl.

19. (Amended) A pharmaceutical composition for the alleviation of inflammatory and cardiovascular disorders in mammals for topical, oral, parenteral and aerosol administration, comprising an effective amount of a substituted pyrazole compound [according to claim 1] as in any of claims 7, 9-12 or 15-18 as active ingredient dispersed in a pharmaceutically acceptable carrier.

23. (Amended) A method for treating myocardial insufficiencies, including angina, vasospasm, infarction, comprising administering to said mammal a pharmaceutical composition comprising an amount effective against myocardial insufficiency, of a substituted pyrazole compound [according to claim 1] as in any of claims 7, 9-12 or 15-18 as active ingredient dispersed in a pharmaceutically acceptable carrier.

Claim 9, line 1, delete "of claim 1".

Claim 10, line 1, delete "claim 1" and substitute therefor --claim 7--.

Claim 11, line 1, delete "claim 1" and substitute therefor --claim 7--.

Claim 12, line 1, delete "claim 1" and substitute therefor --claim 7--.

Claim 15, line 1, delete "of claim 1".

Claim 16, line 1, delete "of claim 1".

Claim 17, line 1, delete "of claim 1".

line 2, delete "N-carboxymethyl-3-[5-(4-chlorophenyl)-"

line 3, delete "1-(4-methoxyphenyl)-3-pyrazolyl] propanamide."

Cancel claims 6, 8, 13, 14 and 25 without prejudice.

Add the following claim.

~~31.~~ A compound having a structure that corresponds to the formula:



wherein

R_1 and R_3 are selected from the group consisting of halo, trifluoromethyl and methyl and X is selected from the group consisting of $-C(O)-R_5$ wherein R_5 is selected from the group consisting of $-N(CH_3)OH$, -N(t-butyl)OH, -N(i-propyl)OH, -N(cyclohexyl)OH, -N(ethyl)OH and -N(phenyl)OH or R_5 is $-NHCH_2CO_2H$, or X is $-CH_2NH_2$, -C(O)H or -C(=NOH)H.